Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.41 USD
-1.04 (-0.94%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $109.15 -0.26 (-0.24%) 5:54 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
JAZZ 109.41 -1.04(-0.94%)
Will JAZZ be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
Other News for JAZZ
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
Wells downgrades Zymeworks with zanidatamab approval priced in
Wells downgrades Zymeworks with zanidatamab approval priced in
Court ruling removes ‘last binary risk’ for Avadel, says H.C. Wainwright
Court ruling removes 'last binary risk' for Avadel, says H.C. Wainwright